anti-interleukin-6 - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %lownot evaluable highcrucial-
deaths 1.52 [0.41, 5.62]< 10%1 study (1/-)26.6 %lownot evaluable highcrucial-
clinical deterioration 1.11 [0.59, 2.09]< 10%1 study (1/-)37.4 %lownot evaluable highimportant-
clinical improvement 1.06 [0.80, 1.41]> 10%1 study (1/-)65.7 %lownot evaluable highimportant-
death or ventilation 0.83 [0.38, 1.81]< 10%1 study (1/-)68.0 %lownot evaluable highimportant-

safety endpoints 00

serious adverse events 1.21 [0.58, 2.53]< 10%1 study (1/-)30.6 %lownot evaluable highimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.